Biomea Fusion Inc

NASDAQ BMEA

Data sourced from

and

Download Data

Biomea Fusion Inc Total Liabilities for the quarter ending March 31, 2024: USD 33.18 M

Biomea Fusion Inc Total Liabilities is USD 33.18 M for the quarter ending March 31, 2024, a 12.44% change year over year. Total Liabilities is the total amount of a company's debts and other obligations.

Biomea Fusion Inc Total Liabilities for the quarter ending March 31, 2023 was USD 29.51 M, a 192.20% change year over year.
Biomea Fusion Inc Total Liabilities for the quarter ending March 31, 2022 was USD 10.10 M, a -83.07% change year over year.
Biomea Fusion Inc Total Liabilities for the quarter ending March 31, 2021 was USD 59.65 M.

NASDAQ: BMEA

Biomea Fusion Inc

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road, Redwood City, CA, United States, 94063
Employees	110
Sector	Healthcare
Industry	Biotechnology

Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends